Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acetylation of SERCA2a, Another Target for Heart Failure Treatment?

Literature DB >> 31021723

Acetylation of SERCA2a, Another Target for Heart Failure Treatment?

Xiongwen Chen¹, Xiaoying Zhang¹, Scott Gross², Steven R Houser¹, Jonathan Soboloff².

Abstract

Entities: Chemical Disease Gene Species

Keywords: Editorials; acetylation; action potential; heart failure; sarcoplasmic reticulum

Mesh：

Substances：

Year: 2019 PMID： 31021723 PMCID： PMC6564686 DOI： 10.1161/CIRCRESAHA.119.315017

Source DB: PubMed Journal: Circ Res ISSN： 0009-7330 Impact factor: 17.367

× No keyword cloud information.

18 in total

1. Compromised myocardial energetics in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2a.

Authors: Ilka Pinz; Rong Tian; Darrell Belke; Eric Swanson; Wolfgang Dillmann; Joanne S Ingwall
Journal: J Biol Chem Date: 2011-01-29 Impact factor: 5.157

Review 2. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism.

Authors: Ruben Nogueiras; Kirk M Habegger; Nilika Chaudhary; Brian Finan; Alexander S Banks; Marcelo O Dietrich; Tamas L Horvath; David A Sinclair; Paul T Pfluger; Matthias H Tschöp
Journal: Physiol Rev Date: 2012-07 Impact factor: 37.312

3. Ablation of phospholamban and sarcolipin results in cardiac hypertrophy and decreased cardiac contractility.

Authors: Mayilvahanan Shanmugam; Shumin Gao; Chull Hong; Nadezhda Fefelova; Martha C Nowycky; Lai-Hua Xie; Muthu Periasamy; Gopal J Babu
Journal: Cardiovasc Res Date: 2010-09-10 Impact factor: 10.787

4. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model.

Authors: Sven T Pleger; Changguang Shan; Jan Ksienzyk; Raffi Bekeredjian; Peter Boekstegers; Rabea Hinkel; Stefanie Schinkel; Barbara Leuchs; Jochen Ludwig; Gang Qiu; Christophe Weber; Philip Raake; Walter J Koch; Hugo A Katus; Oliver J Müller; Patrick Most
Journal: Sci Transl Med Date: 2011-07-20 Impact factor: 17.956

5. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide.

Authors: Takeshi Adachi; Robert M Weisbrod; David R Pimentel; Jia Ying; Victor S Sharov; Christian Schöneich; Richard A Cohen
Journal: Nat Med Date: 2004-10-17 Impact factor: 53.440

6. Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure.

Authors: Changwon Kho; Ahyoung Lee; Dongtak Jeong; Jae Gyun Oh; Przemek A Gorski; Kenneth Fish; Roberto Sanchez; Robert J DeVita; Geir Christensen; Russell Dahl; Roger J Hajjar
Journal: Nat Commun Date: 2015-06-12 Impact factor: 14.919

7. Inhibition of miR-25 improves cardiac contractility in the failing heart.

Authors: Christine Wahlquist; Dongtak Jeong; Agustin Rojas-Muñoz; Changwon Kho; Ahyoung Lee; Shinichi Mitsuyama; Alain van Mil; Woo Jin Park; Joost P G Sluijter; Pieter A F Doevendans; Roger J Hajjar; Mark Mercola
Journal: Nature Date: 2014-03-12 Impact factor: 49.962

Review 8. The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective.

Authors: Carl Hayward; Nicholas R Banner; Andrew Morley-Smith; Alexander R Lyon; Sian E Harding
Journal: Hum Gene Ther Date: 2015-05 Impact factor: 5.695

Review 9. Calcium in the heart: from physiology to disease.

Authors: David Eisner
Journal: Exp Physiol Date: 2014-08-15 Impact factor: 2.969

10. The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy.

Authors: Catherine A Makarewich; Amir Z Munir; Gabriele G Schiattarella; Svetlana Bezprozvannaya; Olga N Raguimova; Ellen E Cho; Alexander H Vidal; Seth L Robia; Rhonda Bassel-Duby; Eric N Olson
Journal: Elife Date: 2018-10-09 Impact factor: 8.140

6 in total

Review 1. SERCA2a: a key protein in the Ca²⁺ cycle of the heart failure.

Authors: Liu Zhihao; Ni Jingyu; Li Lan; Sarhene Michael; Guo Rui; Bian Xiyun; Liu Xiaozhi; Fan Guanwei
Journal: Heart Fail Rev Date: 2020-05 Impact factor: 4.214

2. MicroRNA‑138‑5p drives the progression of heart failure via inhibiting sirtuin 1 signaling.

Authors: Shuai Sun; Chun Wang; Jianxin Weng
Journal: Mol Med Rep Date: 2021-02-12 Impact factor: 2.952

3. Intermedin protects thapsigargin‑induced endoplasmic reticulum stress in cardiomyocytes by modulating protein kinase A and sarco/endoplasmic reticulum Ca²⁺‑ATPase.

Authors: Zhidong Li; Jia Guo; Yunfei Bian; Mingsheng Zhang
Journal: Mol Med Rep Date: 2020-12-10 Impact factor: 2.952

Acetylation of SERCA2a, Another Target for Heart Failure Treatment?

1. Compromised myocardial energetics in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2a.

Review 2. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism.

3. Ablation of phospholamban and sarcolipin results in cardiac hypertrophy and decreased cardiac contractility.

4. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model.

5. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide.

6. Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure.

7. Inhibition of miR-25 improves cardiac contractility in the failing heart.

Review 8. The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective.

Review 9. Calcium in the heart: from physiology to disease.

10. The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy.

Review 1. SERCA2a: a key protein in the Ca²⁺ cycle of the heart failure.

2. MicroRNA‑138‑5p drives the progression of heart failure via inhibiting sirtuin 1 signaling.

3. Intermedin protects thapsigargin‑induced endoplasmic reticulum stress in cardiomyocytes by modulating protein kinase A and sarco/endoplasmic reticulum Ca²⁺‑ATPase.

4. Intranuclear cardiac troponin I plays a functional role in regulating Atp2a2 expression in cardiomyocytes.

Review 5. Mechanisms underlying pathological Ca²⁺ handling in diseases of the heart.

6. Dysbindin deficiency Alters Cardiac BLOC-1 Complex and Myozap Levels in Mice.

Review 2. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism.

Review 8. The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective.

Review 9. Calcium in the heart: from physiology to disease.

Review 1. SERCA2a: a key protein in the Ca2+ cycle of the heart failure.

Review 5. Mechanisms underlying pathological Ca2+ handling in diseases of the heart.

Review 1. SERCA2a: a key protein in the Ca²⁺ cycle of the heart failure.

Review 5. Mechanisms underlying pathological Ca²⁺ handling in diseases of the heart.